The olfactory systems of dogs are highly sensitive to VOCs, enabling them to detect anything from explosives & drugs to cancer & infection. A similar technological approach can be employed to assist doctors in the detection of the same VOCs.
Sensill is innovating technology to detect VOCs with a proprietary, noninvasive, point-of-care technology.
Sensill is developing a diagnostic system that will allow doctors to rapidly & noninvasively diagnose skin and wound as well as urine infections, plus continuously monitor the response to therapy at the point of care.
Tour our site & contact us through our web form to get in touch. Feel free to learn more about our team on the about us page!
Sensill aims to provide immediate insights, allowing clinicians to make rapid decisions directly at the point of care without waiting for lab results.
Sensill technology intends to help minimize the need for expensive skin biopsies with an economical solution.
Sensill aims to analyze emitted volatile organic compounds within minutes, identifying and quantifying infectious bacteria during the initial diagnosis.
Sensill plans to provide an accurate identification and quantification of infectious bacteria or fungi, comparable to but more efficient than traditional methods.
The Sensill diagnostic system intends to avoid skin biopsies, making it far easier than traditional care. It's designed to be an entirely non-invasive procedure.
The Sensill diagnostic system intends to be easy to carry between patients and battery-operated, making it ideal as a portable device.
The Sensill diagnostic system intends to be easy to use and operate by all health professionals.
Sensill aims to provide a quantitative metabolic readout reflecting the actual level of organism burden, which can help monitor treatment effectiveness.
The platform is designed to be capable of detecting metabolite signatures from any living organism, offering unparalleled versatility beyond its initial focus on skin and urine infections.
Sensill's validated platform is protected by 17 patents, ensuring a powerful and robust new standard in diagnostics.
By providing accurate identification and minimizing broad-spectrum antibiotic use, Sensill aims to contribute to a reduction in the rate of resistance development.
The system is designed to fit into the point-of-care workflow without requiring calibration.
Sensill demonstrates the ability to identify and quantify bacteria, fungi, and subspecies (e.g., MRSA).